We have generated a lot of interest, as both new and existing customers have signed both back-up and primary manufacturing agreements since launching the program.
Durham, N.C. (PRWEB) October 19, 2011
Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry announced that senior executives of the company will be available to discuss the industry success it has generated from its innovative, industry-first sterile pharmaceutical manufacturing back-up supply program to manage the risk of supply interruption Since launching earlier this year, Patheon has generated a tremendous response from companies interested in the program.
Geoffrey M. Glass, Patheon’s Executive Vice President of Global Sales and Marketing said, “With regulatory scrutiny increasing, we recognize how important it is for pharmaceutical companies to have established sterile back-up supply agreements in place. Our program has brought a prudent way to manage the risk of supply interruption without building the capacity internally or committing to onerous volume obligations with a contract manufacturing partner. We have generated a lot of interest, as both new and existing customers have signed both back-up and primary manufacturing agreements since launching the program. They have recognized the benefit of getting an insurance policy on their sterile supply which is largely offset the tech transfer investment.”
Several companies have moved backup, or primary, supply for sterile products since the launch of this program. The Medicines Company, Photocure and others now utilize Patheon’s industry leading facilities in Italy to manufacture their sterile products.
Patheon representatives will be available to discuss the company’s back-up sterile supply program at the upcoming CPhI Worldwide conference in Messe Frankfurt, Germany from October 25 through October 27, 2011. The company will be exhibiting at Booth 40E04 through the duration of the conference. For those companies that are interested in discussing this program and will not be attending the conference, please contact a Patheon representative at 1-866-728-4366.
Patheon Inc. (TSX: PTI) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world’s leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. The company’s integrated development and manufacturing network of 10 facilities, nine development centers and one clinical trial packaging facility across North America and Europe, ensures that customer products can be launched with confidence anywhere in the world.